Dear Jeremy

Apologies for the late reply – I have been off sick in the hospital over the weekend and yesterday, and I have only returned to work today.

We only have one comment to make, related to Section 7.1.2.3.3. Wholesale acquisition costs, pages 300-302. Janssen, as a member of the ABPI, does not support the use of wholesaler acquisition costs for any of the drugs under appraisal in this MTA. We only support the use of BNF list prices, as is usual practice in NICE technology appraisals.

Can I also ask – is there any other precedent for the use of wholesaler acquisition costs in any other appraisal?

Kind regards
[redacted]

[redacted]

Head of Outcomes Research

Janssen-Cilag Ltd UK
50-100 Holmers Farm Way
High Wycombe
Bucks
HP12 4EG
Phone: [redacted]
Fax: [redacted]
Mobile: [redacted]

janssen | PHARMACEUTICAL COMPANIES OF Johnson & Johnson